Question

Which of the following is a STRONG recommendation from the American College of Physicians?

A) Do not monitor BMD during the 5 years of treatment in women with osteoporosis, as evidence suggests that fracture risk may be reduced regardless of BMD changes.
B) In men with clinically recognized osteoporosis, clinicians should offer bisphosphonate therapy to reduce vertebral fracture risk; evidence is lacking on BMD monitoring in men.
C) In postmenopausal women, do not use estrogen or estrogen plus progestogen or raloxifene for the treatment of osteoporosis.
D) In women with osteoporosis, use pharmacologic treatment for 5 years, employing generic drugs used when possible.

Answer 1

Option B. The strong recommendation from the American College of Physicians is to offer bisphosphonate therapy to men with clinically recognized osteoporosis to reduce the risk of vertebral fractures.

Step-by-step explanation:

Among the strong recommendations from the American College of Physicians, one stands out: In men with clinically recognized osteoporosis, clinicians should offer bisphosphonate therapy to reduce vertebral fracture risk; evidence is lacking on Bone Mineral Density (BMD) monitoring in men. This approach aligns with current treatments for managing osteoporosis, which include bisphosphonates, due to their ability to slow down the breakdown of bone, allowing for bone rebuilding and maintenance of bone density, ultimately decreasing the risk of fractures.

Additionally, preventing osteoporosis is crucial, involving the elimination of controllable risk factors through behavioral changes such as maintaining a nutritious diet with adequate vitamin D and engaging in weight-bearing exercise, which are important in building bone mass. For those already diagnosed with osteoporosis or at high risk, treatment with bisphosphonates can significantly reduce the risk of fractures.